USFDA gives nod to Alembic Pharma’s genetic formulation to treat heart failure

Alembic Pharmaceuticals Limited has received final approval from the USFDA for its ANDA Ivabradine Tablets, 5 mg and 7.5 mg, which are therapeutically equivalent to Amgen’s Corlanor Tablets. The drug is used to reduce the risk of hospitalization for worsening heart failure and has an estimated market size of US$ 145.3 million. Alembic has a […]